Imaging of nonmotor symptoms in Parkinson syndromes

Clinical Neuroscience

Volumn 5, Issue 2, 1998, Pages 115-120

  Paulus, Walter ^a,b,d   Trenkwalder, Claudia ^c  

^a Department of Clinical Neurophysiology ^*  (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Depression; Imaging; Neuropsychology; Parkinson's disease; PET; SPECT

Indexed keywords

BRAIN METABOLISM; DEMENTIA; DEPRESSION; DIAGNOSTIC IMAGING; FRONTAL CORTEX; HALLUCINATION; HUMAN; NEUROPSYCHOLOGY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY;

BRAIN; HUMAN; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032470569     PISSN: 10656766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Alpperspach EMH, Vieregge P, Pulkowski U, Koempf D (1996): Clinical concomitants of hallucinations in Parkinson's disease: a hospital-based case-control study. Neurology 46:A144.
2. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997): Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12:33-38.
3. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D, Cornu P, Pidoux B, Samson Y, Agid Y (1999): Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 340:1476-1480.
4. Bissessur S, Tissingh G, Wolters EC, Scheltens P (1997): rCBF SPECT in Parkinson's disease patients with mental dysfunction. J Neural Transm Suppl 50:25-30.
5. Brooks DJ (1997a): Advances in imaging Parkinson's disease. Curr Opin Neurol 10:327-331.
6. Brooks DJ (1997b): PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol 6:69-87.
7. Brooks DJ (1998a): The early diagnosis of Parkinson's disease. Ann Neurol 44:510-8.
8. Brooks DJ (1998b): Positron emission tomography studies in movement disorders. Neurosurg Clin N Am 9:263-282.
9. Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR Jr, Duvoisin RC, Harding AE, Marsden CD, Brooks DJ (1992): Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 42:1894-1900.
10. Buttner T, Kuhn W, Muller T, Welter FL, Federlein J, Heidbrink K, Przuntek H (1996): Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J Neural Transm 103:1195-1204.
11. Dierks T, Linden DE, Jandl M, Formisano E, Goebel R, Lanfermann H, Singer W (1999): Activation of Heschl's gyrus during auditory hallucinations. Neuron 22:615-621.
12. Dubois B, Pillon B (1997): Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8.
13. Eidelberg D, Moeller JR, Dhawan V, Spetsleris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, et al (1994): The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-801.
14. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsleris P, Silbersweig D, Stern E, Woods RP, Fazzini E, Dogali M, Beric A (1996): Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 39:450-459.
15. Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, Spetsieris P, Alterman R, Kelly PJ, Dogali M, Fazzini E, Beric A (1997): Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 120:1315-1324.
16. Eising EG, Muller TT, Zander C, Kuhn W, Farahati J, Reiners C, Coenen HH (1997): SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease. J Invest Med 45:448-452.
17. Friedman JH, Max J, Swift R (1987): Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clin Neuropharmacol 10:470-475.
18. Gotham AM, Brown RG, Marsden CD (1988): 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 111:299-321.
19. Graham JM, Grunewald RA, Sagar HJ (1997): Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 63:434-440.
20. Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S (1997): [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48: 1578-1583.
21. Heiss WD, Wurker M (1999): Value of functional imaging in Parkinson's disease and related movement disorders. Nervenarzt 70 (Suppl 1):S2-10.
22. Hoflich G, Burghof KW, Kasper S, Moller HJ (1994): Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease. Nervenarzt 65:202-205.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
24. Ichise M, Kim Y, Ballinger J, Vines D, Erami S, Tanaka F, Lang A (1999): SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa untreated PD. Neurology 52:1206-1214.
25. Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost JJ (1999): PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology 52:1221-1226.
26. Jagust WJ, Reed BR, Martin EM, Eberling JL, Nelson-Abbott RA (1992): Cognitive function and regional cerebral blood flow in Parkinson's disease. Brain 115: 521-537.
27. Jahanshahi M, Jenkins IH, Brown RG, Marsden CD, Passingham RE, Brooks DJ (1995): Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 118:913-933.
28. Jolles PR, Chapman PR, Alavi A (1989): PET, CT, and MRI in the evaluation of neuropsychiatric disorders: current applications. J Nucl Med 30:1589-1606.
29. Kim SE, Lee WY, Choc YS, Kim JH (1999): SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res 21:255-261.
30. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH (1999a): The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 56:225-228.
31. Kraft E, Winkelmann J, Trenkwalder C, Auer DP (1999b): Visual hallucinations, white matter lesions and disease severity in Parkinson's disease. Acta Neurologica Scand 98:1-6.
32. Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P (1993): Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123. Arch Neurol 50:509-512.
33. Lepore FE (1997): Visual loss as a causative factor in visual hallucinations associated with Parkinson disease. Arch Neurol 54:799.
34. Maes M, Dierckx R, Meitzer HY, Ingels M, Schotte C, Vandewoude M, Calabrese J, Cosyns P (1993): Regional cerebral blood flow in unipolar depression measured with Tc-99m-HMPAO single photon emission computed tomography: negative findings. Psychiatry Res 50:77-88.
35. Mayberg HS, Starkstein SE, Sadzot B, Prezlosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990): Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 28:57-64.
36. Nishiyama K, Mizuno T, Sakuta M, Kurisaki H, Momose T (1991): Chronic dementia in Parkinson disease treated by long-term administration of anticholinergic drug-evaluation of neuropsychological test, PET, and SPECT. Rinsho Shinkeigaku 31:625-631.
37. Otsuka M, Kuwabara Y, Ichiya Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K (1997): Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med 11:251-257.
38. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995): Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 33:1-24.
39. Owen AM, Doyon J, Dagher A, Sadlkot A, Evans AC (1998): Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 121:949-965.
40. Pizzolato G, Dam M, Borsato N, Saitta B, Da Col C, Perlotto N, Zanco P, Ferlin G, Battistin L (1988): [99mTc]-HM-PAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab 8:5101-108.
41. Quinn N (1989): Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry Suppl:78-89.
42. Rascol O, Sabatini U, Chollet F, Fabre N, Senard JM, Montastruc JL, Celsis P, Marc-Vergnes JP, Rascol A (1994): Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry 57:567-571.
43. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996): Visual hallucinations associated with Parkinson disease. Arch Neurol 53:1265-1268.
44. Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Volgt K, Dichgans J, Klockgether T (1999): Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45: 65-74.
45. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH (1992): 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism [published erratum appears in Neurology 1992 May;42(5):1028]. Neurology 42:556-561.
46. Schwarz J, Scherer J, Trenkwalder C, Mozley PD, Tatsch K (1998): Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res 83:23-28.
47. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF (1997): Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 24:415-421.
48. Troster AI, Staip LD, Paolo AM, Fields JA, Koller WC (1995): Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 52:1164-1169.
49. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE (1997): Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 38:797-802.
50. Weinstein HC, Scheltens P, Hijdra A, van Royen EA (1993): Neuro-imaging in the diagnosis of Alzheimer's disease. II. Positron and single photon emission tomography. Clin Neurol Neurosurg 95: 81-91.